DXR

DAXOR CORP (10-Q) Filing Summary

Business Context and Reporting Period

Company: DAXOR CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Daxor is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer and related diagnostic kits. It also operates a cryobanking subsidiary (Scientific Medical Systems Corp) for blood and semen storage. A significant portion of the company's financial activity involves an investment portfolio of utility stocks and derivatives, managed to offset operating losses.

Key Financial Metrics (Six Months Ended June 30, 2010)

Material Changes vs. Prior Period

• Revenue Decline: Total operating revenues decreased 6.12% to $764,604 from $814,457 in the prior year period. This was driven by a 9.10% drop in blood volume kit sales (1,621 kits sold vs. 1,851 previously).
• Operating Loss Expansion: The operating loss widened to $(2,847,226) from $(2,460,602), primarily due to a 30% increase in R&D expenses ($1.63M vs. $1.27M) and higher professional fees.
• Investment Volatility: While realized gains on securities increased significantly ($11.9M vs. $5.5M), the company recorded a mark-to-market loss on short positions of $(9.4M), compared to a gain of $0.78M in the prior year. This volatility reduced total other income to $3.5M from $7.7M.
• Liquidity: Cash and cash equivalents decreased to $213,402 from $277,088 at year-end 2009. Net cash used in operating activities was $2.63M.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• R&D Focus: Management is increasing R&D spend to establish blood volume analysis as a standard of care in heart failure, critical care, and surgery. New projects include Glomerular Filtration Rate (GFR) testing and a needle-free delivery device ("Max-200").
• Clinical Studies: The company is preparing for the TEAM-HF study (300 patients) to assess the impact of blood volume data on heart failure outcomes. Enrollment is anticipated in Q3 2010.
• Investment Strategy: The investment portfolio remains critical to offsetting operating losses. The company intends to sell approximately 100,000 additional shares of Dynegy, Inc. in late 2010 to realize tax losses and lower the cost basis of remaining holdings.

• SEC Investigation: The company and CEO Dr. Joseph Feldschuh received Wells Notices in 2005, 2007, and 2009 regarding potential violations of the Investment Company Act (operating as an unregistered investment company). Dr. Feldschuh was subpoenaed for a deposition in June 2010. No closing notice has been received.
• Key Person Risk: Dr. Feldschuh is the sole manager of the investment portfolio and the primary scientific authority. His inability to continue would materially reduce investment returns and impact scientific development.
• Reimbursement Policy: CMS policy changes in 2008 eliminated separate Medicare reimbursement for diagnostic radiopharmaceuticals (Volumex), requiring hospitals to absorb costs. The impact on private insurers remains uncertain.
• Customer Concentration: Four hospitals accounted for 58.77% of blood volume kit sales in the first six months of 2010.

Investor Verification Checklist

• Investment Portfolio Valuation: Verify the fair value of the $48.8M available-for-sale securities portfolio, specifically the unrealized losses on Dynegy ($1.58M) and Citigroup ($0.71M).
• SEC Status: Monitor for any formal enforcement actions or closing notices regarding the Wells Notices and the June 2010 deposition.
• Operating Cash Flow: Assess the sustainability of the $2.63M cash burn from operations and the reliance on investment income to fund R&D and dividends.
• Customer Concentration: Evaluate the risk associated with four hospitals representing nearly 60% of kit sales revenue.
• Regulatory Reimbursement: Track any changes in private insurance reimbursement policies for Volumex kits following the CMS policy shift.